小儿豉翘清热颗粒联合孟鲁司特治疗儿童支原体肺炎的临床效果观察

Clinical Efficacy of Xiao’er Chiqiao Qingre Granule Combined with Monelukast on Mycoplasma Pneumonia in Children

目的:探究小儿豉翘清热颗粒联合孟鲁司特治疗儿童支原体肺炎(MPP)的临床效果。方法:选取2021年2月—2022年1月英山县人民医院儿科收治的76例儿童MPP患儿为研究对象,采用随机分组法将其分为观察组与对照组,各38例。对照组采用西医常规方法治疗,观察组在此基础上使用小儿豉翘清热颗粒联合孟鲁司特治疗。比较两组治疗前后免疫功能、血清炎症因子水平,观察两组临床各项指标改善时间、临床疗效与不良反应发生情况。结果:治疗后,两组CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平均较治疗前显著升高,CD8^(+)水平较治疗前显著降低,观察组CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平均高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(P<0.05)。治疗后,两组白细胞介素-5(IL-5)、白细胞介素-6(IL-6)水平均较治疗前显著降低,白细胞介素-10(IL-10)水平较治疗前显著升高,观察组IL-5、IL-6水平均低于对照组,IL-10水平高于对照组,差异有统计学意义(P<0.05)。观察组咳嗽消失时间、湿啰音消失时间、胸片恢复时间、退热时间均显著早于对照组,差异有统计学意义(P<0.05)。观察组临床总有效率为89.47%,显著高于对照组的71.05%,差异有统计学意义(P<0.05)。观察组不良反应总发生率为5.26%,略低于对照组的7.89%,但两组比较,差异无统计学意义(P>0.05)。结论:使用小儿豉翘清热颗粒联合孟鲁司特治疗能有效提高MPP的临床效果,不增加不良反应,改善炎症因子水平,提高儿童细胞免疫水平。

Objective:To explore the clinical effect of Xiao’er Chiqiao Qingre Granule combined with Monelukast in the treatment of mycoplasma pneumonia in children.Method:A total of 76 children with mycoplasma pneumonia admitted to the Department of Pediatrics of the People's Hospital of Yingshan from February 2021 to January 2022 were selected as the study objects,and they were randomly divided into observation group and control group,with 38 cases in each group.The control group was treated with conventional Western medicine,and the observation group was treated with Xiao’er Chiqiao Qingre Granule combined with Monelukast.The immune function and serum inflammatory factors were compared between the two groups before and after treatment,and the improvement time,clinical efficacy and adverse reactions of the two groups were observed.Result:After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in both groups were significantly higher than before treatment,while the levels of CD8^(+)were significantly lower than before treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,while the levels of CD8^(+)was lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of interleukin-5(IL-5)and interleukin-6(IL-6)in the two groups were significantly lower than before treatment,and the levels of interleukin-10(IL-10)were significantly higher than before treatment,the levels of IL-5 and IL-6 in the observation group were lower than those in the control group,and the levels of IL-10 were higher than those in the control group,the differences were statistically significant(P<0.05).The disappearance time of cough,the disappearance time of moist rales,the recovery time of chest film and the fever in the observation group were significantly earlier than those in the control group,the differences were statistically significant(P<0.05).The total clinical effective rate of the observation group was 89.47%,which was significantly higher than 71.05%of the control group,the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 5.26%,slightly lower than 7.89%in the control group,but there was no statistical significance between the two groups(P>0.05).Conclusion:The combination of Xiao’er Chiqiao Qingre Granule and Monelukast can effectively improve the clinical effect of MPP,without increasing adverse reactions,improve the level of inflammatory factors,and enhance the level of cellular immunity in children.